venBio Global Strategic Fund II L.P. → Menlo Therapeutics Inc. VYNE

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 11/100

Passive Schedule 13G filer baseline
Short interest building (+76.3% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

2 transactions

2 buys · 0 sales · 0 awards/exercises

Issuer Cluster

6 13D/G filings on this issuer

5 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-07-15

DTC 1.00

183,974 shares short · +76.3% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-07-27	Ashiya Mona	director	Award	15,435	$28.56	$441K
2026-07-27	Zeronda Tyler	director	Award	185,798	$28.56	$5.31M

Other 13D/G Filings on Menlo Therapeutics Inc.

Filed	Form	Filer	Stake	Shares
2026-10-07	SCHEDULE 13G	Bellevue Group AG	—	—	view →
2026-09-17	SCHEDULE 13G	Invus Global Management, LLC	—	—	view →
2026-08-14	SCHEDULE 13G	ADAR1 Capital Management, LLC	—	—	view →
2026-08-05	SCHEDULE 13D	ORBIMED ADVISORS LLC	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D/A	AI Biotechnology LLC	6.02%	178,180	view →

Other Filings by venBio Global Strategic Fund II L.P.

Filed	Form	Issuer	Stake	Shares
2021-05-07	SC	Akero Therapeutics, Inc.	—	—	view →
2020-09-09	SC	Akero Therapeutics, Inc.	—	—	view →
2020-01-15	SC	Akero Therapeutics, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →